HER2 in gastric cancer: An immunohistochemical study on tissue microarrays and the coressponding whole-tissue sections with a supplemental fish study

Pathology and Oncology Research

Volumn 19, Issue 4, 2013, Pages 855-865

  Gasljevic, Gorana ^a   Lamovec, Janez ^a   Contreras, Juan Antonio ^a   Zadnik, Vesna ^a   Blas, Mateja ^a   Gasparov, Slavko ^b,c  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b University of Zagreb   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

FISH; Gastric carcinoma; HER2; Immunohistochemistry; TMA; Whole sections

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HER2 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; STOMACH CANCER; TISSUE MICROARRAY; TISSUE SECTION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84885189137     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9654-9     Document Type: Article

References (32)

1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150
2. Cunningham SC, Kamangar F, Kim MP et al (2005) Survival after gastric adenocarcinoma resection: eighteen-year experience at single institution. J Gastrointest Surg 9:725-728
3. Fayçal J, Bessaguet C, Nousbaum JB et al (2005) Epidemiology and long term survival of gastric carcinoma in the French district of Finestere between 1984 and 1995. Gastroenterol Clin Biol 29:23-32
4. Tsubono Y, Hisamichi S (2000) Screening for gastric cancer in Japan. Gastric Cancer 3:9-18
5. Ohtsu A (2008) Chemotherapy for metastatic gastric cancer: past, present and future. Gastroenterology 43:256-264
6. Menard S, Casalini P, Campiglio M, Pupa S, Agresti R, Tagliabue E (2001) HER2 overexpresion in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol 12:S15-S19
7. Scholl S, Beuzeboc P, Pouillart P (2001) Targeting HER2 in other tumor types. Ann Oncol 12:S81-S87
8. Ross JS, Slodkowska A, Symmans F, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320-368
9. Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523-1529
10. JÇrgensen JT (2010) Targeted HER2 treatment in advanced gastric cancer. Oncology 78:26-33
11. Hofmann M, Stoss O, Shi D et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797-805
12. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM (2000) c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18(11):2201-2209
13. Yano T, Toshihiko D, Ohtsu A et al (2006) Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15:65-71
14. Tanner M, Hollmen M, Junttila TT et al (2005) Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273-278
15. Lordick F, Bang YJ, Kang YK et al. (2007) HER2-positive advanced gastric cancer: similar HER2 positivity levels to breast cancer. P3541, ECCO 14, Barcelona, Spain, September
16. Rüschoff J, Dietel M, Baretton G et al (2010) HER2 diagnostics in gastric cancer - guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457(3):299-307
17. Park DI, Yun JW, Park JH et al (2006) HER2/neu amplification is an independent prognostic factor in gastric carcinoma. Dig Dis Sci 51:1371-1379
18. Drev P, Frkovic-Grazio S, Bracko M (2008) Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma. Appl Immunohistochem Mol Morphol 16(2):179-184
19. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W (2010) HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 32:57-65
20. Lee S, de Boer WB, Fermoyle S, Platten M, Kumarasinghe MP (2011) Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 59:832-840
21. Kunz PL, Mojtahed A, Fisher G et al (2012) HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 20(1):13-24
22. Park SY, Hwang HS, Park HJ et al (2012) Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 43(3):413-422
23. Marx AH, Simon R, Sauter G (2010) HER-2 amplification is highly homogeneous in gastric cancer-reply. Hum Pathol 41:305-306
24. Moelans CB, Milne AN, Morsink FH, Offerhaus GA, van Diest PJ (2011) Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cell Oncol 34:89-95
25. Penault-Llorca F, Bilous M, Dowset M et al (2009) Emerging technologies for assesing HER2 amplification. Am J Clin Pathol 132:539-548
26. Simon R, Mirlacher M, Sauter G (2003) Tissue microarrays in cancer diagnosis. Expert Rev Mol Diagn 3:421-430
27. Sauter G, Mirlacher M (2002) Tissue microarrys for predictive molecular pathology. J Clin Pathol 55:575-576
28. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697
29. Bang YJ, Chung HC, Xu JM et al. (2009) Pathological features of advanced gastric cancer: relationship to human epidermal growth factor receptor 2 positivity in the global screeening programme of the ToGA trial. J Clin Oncol 27(Suppl.15s); Abstract 4556
30. Barros-Silva JD, Leitão D, Afonso L et al (2009) Association of ERBB2 gene status with histopathological parameters and disease specific survival in gastric carcinoma patients. BJC 100:487-493
31. Kim MA, Jung EJ, Lee SH et al (2007) Evaluation of HER2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization and real-time quantitative polymerase chain reaction. Hum Pathol 38:1386-1393
32. Zheng HC, Li X, Hara T, Masuda S et al (2008) Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch 452:525-534